Raising Health
Adapting Biopharma to AI with Greg Meyers
Apr 2, 2024
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, discusses AI's impact on drug discovery with a16z Bio + Health partner Jorge Conde. They explore AI integration strategies, emerging modalities, and tips for startups partnering with biopharma firms.
33:30
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- AI revolutionizes drug discovery in biopharma for better hit rates and targeted approaches.
- Partnerships are vital for advancing AI applications in biopharma, aiming to optimize drug development processes.
Deep dives
AI's Impact on Drug Discovery
AI is revolutionizing drug discovery and development in biopharma, enabling more efficient and targeted approaches. By incorporating machine learning in predicting chemical reactivity, companies like BMS have seen significant improvements in hit rates and are scaling up these methods. The future holds potential for AI to transform research processes, with scientists possibly relying on predictive models before conducting wet lab experiments.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
